





# **ASH 2021 UPDATES**

Congratulations to our NCIS clinicians whose abstracts were selected for oral and poster presentations at the American Society of Hematology Annual Meeting, 11-14 December 2021!

## ORAL PRESENTATIONS



DR SANJAY DE MEL Consultant Haematology-Oncology

Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/ Refractory Lymphoma; A Prospective Study



DR IAN WU Senior Resident Haematology-Oncology

HLA-Haploidentical Hematopoietic Cell Transplantation of Ex Vivo TCRαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back in Adults and Children with Hematological Malignancies: 4-Year Follow-up of Multicenter Study in Singapore

## POSTER PRESENTATIONS



DR ESTHER CHAN Senior Consultant, Haematology-Oncology Cepp in Previously Untreated Patients with Mature T Cell Lymphomas



PROF CHNG WEE JOO Senior Consultant, Haematology-Oncology

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies



DR SANJAY DE MEL Consultant, Haematology-Oncology

Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Finds an Immune Microenvironment Gene Signature That **Correlates with Clinical Outcomes** 



### DR WILLIAM CHAN Senior Resident, Haematology-Oncology

**Evaluating Front Line Treatment Regimens for Waldenstrom** Macroglobulinaemia: A Systematic Review and Meta-Analysis



### DR CHONG LIP LEONG

Senior Resident, Haematology-Oncology

Graft-Vs-Host Disease (GvHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCy) and Thymoglobulin (ATG) Are More Important Determinants of Cytomegalovirus (CMV) Reactivation after Allogeneic Hematopoietic Cell Transplantation (HCT) Than Ex-Vivo T-Cell Depletion in the Era of Pre-Emptive Therapy



### DR EUNICE LAI Senior Resident, Haematology-Oncology

Lenalidomide Compared to Ixazomib Maintenance in Newly Diagnosed

Multiple Myeloma: A Systematic Review and Meta-Analysis



#### DR EDWIN THONG Senior Resident, Haematology-Oncology

Safety, Feasibility and Healthcare Cost Differences between Inpatient and Outpatient Mobilization Chemotherapy for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Single Center Experience